STOCK TITAN

[8-K] Catalyst Pharmaceutical Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Pacific Premier Bancorp, Inc. (PPBI) filed a Form 8-K announcing that it and Columbia Banking System, Inc. have now obtained all required regulatory approvals for their previously disclosed all-stock merger. Approvals were granted by the Federal Reserve Board on 5 Aug 2025, the FDIC on 4 Aug 2025, and earlier by the Oregon Division of Financial Regulation, clearing the way for both the holding-company merger and the subsidiary bank merger.

With regulatory risk removed, the parties expect to close the transaction on or about 31 Aug 2025, pending satisfaction of customary closing conditions contained in the 23 Apr 2025 Merger Agreement. The information is furnished under Item 7.01 (Reg FD) and Item 8.01 (Other Events); no financial statements or earnings metrics accompany the filing. A joint press release is included as Exhibit 99.1, and standard forward-looking-statement cautions are provided.

Pacific Premier Bancorp, Inc. (PPBI) ha presentato un modulo 8-K annunciando che essa e Columbia Banking System, Inc. hanno ottenuto tutte le approvazioni regolamentari necessarie per la loro fusione interamente azionaria precedentemente comunicata. Le approvazioni sono state concesse dalla Federal Reserve Board il 5 agosto 2025, dalla FDIC il 4 agosto 2025 e precedentemente dalla Divisione di Regolamentazione Finanziaria dell'Oregon, aprendo la strada sia alla fusione delle holding che a quella delle banche controllate.

Con il rischio regolamentare rimosso, le parti prevedono di concludere la transazione intorno al 31 agosto 2025, subordinatamente al rispetto delle condizioni di chiusura consuete contenute nell'Accordo di Fusione del 23 aprile 2025. Le informazioni sono fornite ai sensi dell'Elemento 7.01 (Reg FD) e dell'Elemento 8.01 (Altri Eventi); non sono inclusi bilanci o indicatori di risultato nell'invio. Un comunicato stampa congiunto è incluso come Allegato 99.1 e sono fornite le consuete avvertenze sulle dichiarazioni previsionali.

Pacific Premier Bancorp, Inc. (PPBI) presentó un Formulario 8-K anunciando que ella y Columbia Banking System, Inc. han obtenido todas las aprobaciones regulatorias necesarias para su fusión totalmente en acciones previamente divulgada. Las aprobaciones fueron otorgadas por la Junta de la Reserva Federal el 5 de agosto de 2025, por la FDIC el 4 de agosto de 2025 y anteriormente por la División de Regulación Financiera de Oregón, despejando el camino para la fusión tanto de las sociedades holding como de los bancos subsidiarios.

Con el riesgo regulatorio eliminado, las partes esperan cerrar la transacción alrededor del 31 de agosto de 2025, sujeto al cumplimiento de las condiciones habituales de cierre contenidas en el Acuerdo de Fusión del 23 de abril de 2025. La información se proporciona bajo el Punto 7.01 (Reg FD) y el Punto 8.01 (Otros Eventos); no se acompañan estados financieros ni métricas de ganancias en la presentación. Se incluye un comunicado de prensa conjunto como Anexo 99.1 y se proporcionan las advertencias estándar sobre declaraciones prospectivas.

Pacific Premier Bancorp, Inc. (PPBI)는 8-K 양식을 제출하여 자신들과 Columbia Banking System, Inc.가 이전에 공개한 전액 주식 합병에 대해 필요한 모든 규제 승인을 획득했음을 발표했습니다. 연방준비제도이사회는 2025년 8월 5일, FDIC는 2025년 8월 4일, 그리고 이전에 오리건 금융규제국에서 승인을 받아 지주회사 합병과 자회사 은행 합병 모두에 대한 길을 열었습니다.

규제 리스크가 해소됨에 따라, 양 당사자는 2025년 8월 31일경에 거래를 종결할 것으로 예상하며, 이는 2025년 4월 23일 합병 계약서에 포함된 통상적인 종결 조건 충족을 전제로 합니다. 이 정보는 항목 7.01(Reg FD) 및 항목 8.01(기타 이벤트)에 따라 제공되며, 재무제표나 수익 지표는 제출서류에 포함되어 있지 않습니다. 공동 보도자료는 부속서 99.1로 포함되어 있으며, 표준적인 미래 예측 진술 주의사항도 제공됩니다.

Pacific Premier Bancorp, Inc. (PPBI) a déposé un formulaire 8-K annonçant qu’elle et Columbia Banking System, Inc. ont désormais obtenu toutes les approbations réglementaires requises pour leur fusion entièrement en actions précédemment divulguée. Les approbations ont été accordées par le Federal Reserve Board le 5 août 2025, par la FDIC le 4 août 2025, et plus tôt par la Division de régulation financière de l’Oregon, ouvrant la voie à la fusion des sociétés holding ainsi que celle des banques filiales.

Avec le risque réglementaire levé, les parties prévoient de finaliser la transaction aux alentours du 31 août 2025, sous réserve de la satisfaction des conditions habituelles de clôture contenues dans l’accord de fusion du 23 avril 2025. Les informations sont fournies conformément aux points 7.01 (Reg FD) et 8.01 (Autres événements) ; aucun état financier ni indicateur de résultats n’accompagne le dépôt. Un communiqué de presse conjoint est inclus en annexe 99.1, avec les avertissements habituels concernant les déclarations prospectives.

Pacific Premier Bancorp, Inc. (PPBI) hat ein Formular 8-K eingereicht und bekanntgegeben, dass sie und Columbia Banking System, Inc. nun alle erforderlichen behördlichen Genehmigungen für ihre zuvor angekündigte Aktienfusion erhalten haben. Die Genehmigungen wurden am 5. August 2025 vom Federal Reserve Board, am 4. August 2025 von der FDIC und zuvor von der Oregon Division of Financial Regulation erteilt, was den Weg für die Fusion der Holdinggesellschaften sowie der Tochterbanken frei macht.

Da das regulatorische Risiko beseitigt ist, erwarten die Parteien, die Transaktion am oder um den 31. August 2025 abzuschließen, vorbehaltlich der Erfüllung der üblichen Abschlussbedingungen im Fusionsvertrag vom 23. April 2025. Die Informationen werden gemäß Punkt 7.01 (Reg FD) und Punkt 8.01 (Sonstige Ereignisse) bereitgestellt; es sind keine Finanzberichte oder Gewinnkennzahlen beigefügt. Eine gemeinsame Pressemitteilung ist als Anlage 99.1 enthalten, und es werden die üblichen Hinweise zu zukunftsgerichteten Aussagen gegeben.

Positive
  • All Federal Reserve, FDIC and state approvals obtained, removing primary regulatory risk to the merger timetable.
  • Target closing date set for ~31 Aug 2025, providing clarity for shareholders and arbitrageurs.
Negative
  • Transaction still subject to customary closing conditions; integration and dilution risks highlighted in forward-looking statements.

Insights

TL;DR: All regulatory approvals secured, materially de-risking Pacific Premier’s sale to Columbia and clearing path to 31 Aug close.

Regulatory clearance is the principal gating item in bank mergers; obtaining Fed and FDIC approval eliminates the deal’s largest uncertainty. Because consideration is fixed in stock, PPBI shareholders now have line-of-sight to share exchange and implied premium, while Columbia can begin integration planning in earnest. Remaining conditions are largely mechanical (share listings, legal opinions). The update therefore has a positive, high-confidence impact on deal completion probability and timeline.

TL;DR: Filing is impactful; clears final hurdles but reminds of integration and dilution risks for Columbia.

For PPBI holders, upside is capped at exchange ratio already set; today’s news mainly tightens timing spreads. For Columbia investors, strategic rationale (larger West-Coast footprint, scale efficiencies) can be pursued sooner, yet integration risk, cost saves execution, and potential credit-quality divergence remain. Overall disclosure is net positive, but valuation effects will hinge on market views of post-merger earnings accretion.

Pacific Premier Bancorp, Inc. (PPBI) ha presentato un modulo 8-K annunciando che essa e Columbia Banking System, Inc. hanno ottenuto tutte le approvazioni regolamentari necessarie per la loro fusione interamente azionaria precedentemente comunicata. Le approvazioni sono state concesse dalla Federal Reserve Board il 5 agosto 2025, dalla FDIC il 4 agosto 2025 e precedentemente dalla Divisione di Regolamentazione Finanziaria dell'Oregon, aprendo la strada sia alla fusione delle holding che a quella delle banche controllate.

Con il rischio regolamentare rimosso, le parti prevedono di concludere la transazione intorno al 31 agosto 2025, subordinatamente al rispetto delle condizioni di chiusura consuete contenute nell'Accordo di Fusione del 23 aprile 2025. Le informazioni sono fornite ai sensi dell'Elemento 7.01 (Reg FD) e dell'Elemento 8.01 (Altri Eventi); non sono inclusi bilanci o indicatori di risultato nell'invio. Un comunicato stampa congiunto è incluso come Allegato 99.1 e sono fornite le consuete avvertenze sulle dichiarazioni previsionali.

Pacific Premier Bancorp, Inc. (PPBI) presentó un Formulario 8-K anunciando que ella y Columbia Banking System, Inc. han obtenido todas las aprobaciones regulatorias necesarias para su fusión totalmente en acciones previamente divulgada. Las aprobaciones fueron otorgadas por la Junta de la Reserva Federal el 5 de agosto de 2025, por la FDIC el 4 de agosto de 2025 y anteriormente por la División de Regulación Financiera de Oregón, despejando el camino para la fusión tanto de las sociedades holding como de los bancos subsidiarios.

Con el riesgo regulatorio eliminado, las partes esperan cerrar la transacción alrededor del 31 de agosto de 2025, sujeto al cumplimiento de las condiciones habituales de cierre contenidas en el Acuerdo de Fusión del 23 de abril de 2025. La información se proporciona bajo el Punto 7.01 (Reg FD) y el Punto 8.01 (Otros Eventos); no se acompañan estados financieros ni métricas de ganancias en la presentación. Se incluye un comunicado de prensa conjunto como Anexo 99.1 y se proporcionan las advertencias estándar sobre declaraciones prospectivas.

Pacific Premier Bancorp, Inc. (PPBI)는 8-K 양식을 제출하여 자신들과 Columbia Banking System, Inc.가 이전에 공개한 전액 주식 합병에 대해 필요한 모든 규제 승인을 획득했음을 발표했습니다. 연방준비제도이사회는 2025년 8월 5일, FDIC는 2025년 8월 4일, 그리고 이전에 오리건 금융규제국에서 승인을 받아 지주회사 합병과 자회사 은행 합병 모두에 대한 길을 열었습니다.

규제 리스크가 해소됨에 따라, 양 당사자는 2025년 8월 31일경에 거래를 종결할 것으로 예상하며, 이는 2025년 4월 23일 합병 계약서에 포함된 통상적인 종결 조건 충족을 전제로 합니다. 이 정보는 항목 7.01(Reg FD) 및 항목 8.01(기타 이벤트)에 따라 제공되며, 재무제표나 수익 지표는 제출서류에 포함되어 있지 않습니다. 공동 보도자료는 부속서 99.1로 포함되어 있으며, 표준적인 미래 예측 진술 주의사항도 제공됩니다.

Pacific Premier Bancorp, Inc. (PPBI) a déposé un formulaire 8-K annonçant qu’elle et Columbia Banking System, Inc. ont désormais obtenu toutes les approbations réglementaires requises pour leur fusion entièrement en actions précédemment divulguée. Les approbations ont été accordées par le Federal Reserve Board le 5 août 2025, par la FDIC le 4 août 2025, et plus tôt par la Division de régulation financière de l’Oregon, ouvrant la voie à la fusion des sociétés holding ainsi que celle des banques filiales.

Avec le risque réglementaire levé, les parties prévoient de finaliser la transaction aux alentours du 31 août 2025, sous réserve de la satisfaction des conditions habituelles de clôture contenues dans l’accord de fusion du 23 avril 2025. Les informations sont fournies conformément aux points 7.01 (Reg FD) et 8.01 (Autres événements) ; aucun état financier ni indicateur de résultats n’accompagne le dépôt. Un communiqué de presse conjoint est inclus en annexe 99.1, avec les avertissements habituels concernant les déclarations prospectives.

Pacific Premier Bancorp, Inc. (PPBI) hat ein Formular 8-K eingereicht und bekanntgegeben, dass sie und Columbia Banking System, Inc. nun alle erforderlichen behördlichen Genehmigungen für ihre zuvor angekündigte Aktienfusion erhalten haben. Die Genehmigungen wurden am 5. August 2025 vom Federal Reserve Board, am 4. August 2025 von der FDIC und zuvor von der Oregon Division of Financial Regulation erteilt, was den Weg für die Fusion der Holdinggesellschaften sowie der Tochterbanken frei macht.

Da das regulatorische Risiko beseitigt ist, erwarten die Parteien, die Transaktion am oder um den 31. August 2025 abzuschließen, vorbehaltlich der Erfüllung der üblichen Abschlussbedingungen im Fusionsvertrag vom 23. April 2025. Die Informationen werden gemäß Punkt 7.01 (Reg FD) und Punkt 8.01 (Sonstige Ereignisse) bereitgestellt; es sind keine Finanzberichte oder Gewinnkennzahlen beigefügt. Eine gemeinsame Pressemitteilung ist als Anlage 99.1 enthalten, und es werden die üblichen Hinweise zu zukunftsgerichteten Aussagen gegeben.

NASDAQ false 0001369568 0001369568 2025-08-06 2025-08-06
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 6, 2025

 

 

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

 

 

 

Delaware   001-33057   76-0837053

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

355 Alhambra Circle  
Suite 801  
Coral Gables, Florida   33134
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code:   (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Name of Exchange

on Which Registered

 

Ticker

Symbol

Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 8.01

Other Events

On August 6, 2025, the Company issued a press release announcing its results of operations for the three and six months ended June 30, 2025 and providing a business update. A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)    Exhibits
99.1    Press release issued by the Company on August 6, 2025.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Catalyst Pharmaceuticals, Inc.
By:  

/s/ Michael Kalb

 

Michael Kalb

 

Executive Vice President and CFO

Dated: August 6, 2025

 

3

FAQ

What did Pacific Premier Bancorp (PPBI) disclose in its 8-K?

PPBI reported that all regulatory approvals for its all-stock merger with Columbia Banking System have been obtained.

Which regulators approved the PPBI–Columbia merger?

Federal Reserve Board (5 Aug 2025), FDIC (4 Aug 2025) and the Oregon Division of Financial Regulation.

When is the PPBI–Columbia merger expected to close?

The companies expect to close on or about 31 August 2025, subject to remaining customary conditions.

Does the 8-K include new financial results for PPBI?

No. The filing is limited to regulatory and procedural updates; it contains no earnings or balance-sheet data.

Where can investors find the joint press release related to the merger?

The press release is filed as Exhibit 99.1 to this Form 8-K.
Catalyst Pharmaceuticals Inc

NASDAQ:CPRX

CPRX Rankings

CPRX Latest News

CPRX Latest SEC Filings

CPRX Stock Data

2.71B
114.47M
6.22%
83.62%
7.31%
Biotechnology
Pharmaceutical Preparations
Link
United States
CORAL GABLES